Breakthroughs in therapies for NASH and remaining challenges

V Ratziu, S Francque, A Sanyal - Journal of hepatology, 2022 - Elsevier
Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …
被引用次数：97 相关文章
[PDF] fibronest.com

[PDF][PDF] Breakthroughs in therapies for NASH and remaining challenges

V Ratziu, S Francque, A Sanyal10 - Journal of Hepatology, 2022 - fibronest.com
Initially a condition that received limited recognition and whose clinical impact was
controversial, nonalcoholic steatohepatitis (NASH) has become a leading cause of chronic …

Breakthroughs in therapies for NASH and remaining challenges

V Ratziu, S Francque, A Sanyal - Journal of hepatology, 2022 - pubmed.ncbi.nlm.nih.gov
Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …

Breakthroughs in therapies for NASH and remaining challenges

V Ratziu, S Francque, A Sanyal - Journal of hepatology …, 2022 - repository.uantwerpen.be
Initially a condition that received limited recognition and whose clinical impact was
controversial, nonalcoholic steatohepatitis (NASH) has become a leading cause of chronic …

Breakthroughs in therapies for NASH and remaining challenges

V Ratziu, S Francque, A Sanyal - Journal of Hepatology, 2022 - journal-of-hepatology.eu
Initially a condition that received limited recognition and whose clinical impact was
controversial, non-alcoholic steatohepatitis (NASH) has become a leading cause of chronic …

[引用][C] Breakthroughs in therapies for NASH and remaining challenges

V Ratziu, S Francque, A Sanyal - Journal of Hepatology, 2022 - cir.nii.ac.jp
Breakthroughs in therapies for NASH and remaining challenges | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …